Table 1 Baseline characteristics of 890 IM C_min data from 212 patients with advanced GISTs

Demographic information

Age at diagnosis (years)

56 (49–65)

56 (49–65)

58 (50–65)

0.430^a

Age at blood sampling (years)

61 (53–68)

61 (53–68)

61 (53–67)

0.805^a

Gender

0.708^b

Male

526 (59.10%)

423 (59.41%)

103 (57.87%)

Female

364 (40.90%)

289 (40.59%)

75 (42.13%)

Treatment information

Surgical procedure

0.666^b

Gastrectomy

165 (18.54%)

130 (18.26%)

35 (19.66%)

Non-gastric operation

725 (81.46%)

582 (81.74%)

143 (80.34%)

Daily IM dose

0.324^b

 ≤ 200mg/d

28 (3.15%)

19 (2.67%)

9 (5.06%)

300mg/d

89 (10.00%)

73 (10.25%)

16 (8.99%)

400mg/d

679 (76.29%)

546 (76.69%)

133 (74.72%)

500mg/d

54 (6.07%)

45 (6.32%)

9 (5.06%)

 ≥ 600mg/d

40 (4.49%)

29 (4.07%)

11 (6.18%)

Clinical information

DOG-1

0.144^b

Positive

859 (96.52%)

684 (96.07%)

175 (98.31%)

Negative

31 (3.48%)

28 (3.93%)

3 (1.69%)

CD117

0.771^b

Positive

878 (98.65%)

702 (98.60%)

176 (98.88%)

Negative

12 (1.35%)

10 (1.40%)

2 (1.12%)

CD34

1.000^b

Positive

795 (89.33%)

636 (89.33%)

159 (89.33%)

Negative

95 (10.67%)

76 (10.67%)

19 (10.67%)

Primary tumor site

0.617^b

Stomach

293 (32.92%)

239 (33.57%)

54 (30.34%)

Small intestine

352 (39.55%)

276 (38.76%)

76 (42.70%)

Colorectum

74 (8.31%)

62 (8.71%)

12 (6.74%)

Other

171 (19.21%)

135 (18.96%)

36 (20.22%)

Metastatic site

1.000^b

Liver

405 (45.51%)

324 (45.51%)

81 (45.51%)

Non-liver

485 (54.49%)

388 (54.49%)

97 (54.49%)

Laboratory indicators

WBC (*10⁹/L)

4.32 (3.47–5.39)

4.33 (3.48–5.37)

4.30 (3.46–5.53)

0.852^a

PLT (*10⁹/L)

173 (136–220)

173 (135–217)

178 (137–223)

0.484^a

NEU%

61.25 (53.30–68.90)

61.40 (53.43–69.25)

60.65 (52.05–68.63)

0.422^a

RBC (*10¹²/L)

3.65 (3.27–4.04)

3.64 (3.26–4.02)

3.68 (3.34–4.08)

0.325^a

HB (g/L)

115 (103–126)

115 (102–126)

116 (104–127)

0.387^a

LYM%

27.30 (20.38–35.10)

27.20 (20.33–35.10)

28.35 (20.45–35.73)

0.439^a

ALT (U/L)

16 (12–22)

16 (12–22)

16 (13–24)

0.203^a

AST (U/L)

23 (19–28)

23 (19–28)

23 (19–27)

0.726^a

TBIL (umol/L)

8.70 (6.60–11.70)

8.60 (6.60–11.70)

8.85 (6.48–11.60)

0.624^a

DBIL (umol/L)

3.95 (3.20–5.10)

3.90 (3.20–5.10)

4.00 (3.10–5.20)

0.884^a

IBIL (umol/L)

4.60 (3.20–6.40)

4.50 (3.20–6.40)

4.90 (3.30–6.33)

0.528^a

GGT (U/L)

17 (12–27)

17 (12–27)

17 (12–31)

0.682^a

AKP (U/L)

69 (57–85)

70 (57–85)

69 (58–85)

0.984^a

Cr (umol/L)

82 (71–97)

82 (71–98)

81 (69–95)

0.138^a

BUN (mmol/L)

5.40 (4.40–6.40)

5.40 (4.40–6.50)

5.40 (4.20–6.30)

0.254^a

eGFR (ml/min)

85.35 (69.40–96.15)

85.40 (68.80–96.70)

85.30 (73.98–95.13)

0.490^a